Trovagene (TROV) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TrovaGene (TROV) PT Raised to $7 at Piper Jaffray
March 13, 2015 7:05 AM EDTPiper Jaffray analyst William Quirk reiterated an Overweight rating and lifted his price target on TrovaGene (NASDAQ: TROV) to $7.00 (from $6.25) following Q4 results.
Quirk commented, "Trovagene reported 4Q14 results, with revenue of $56K in line with our $53K estimate; Street (two... More
